For years the European Funding Fund (EIF) was a linchpin of recent funds establishing in the UK (UK). A subsidiary of an EU establishment, the well-funded EIF was an early investor within the funds of many UK-based managers together with such repeat healthcare and life sciences traders as Abingworth Bioventures, Sovereign Capital, and Merlin Biosciences. It additionally made giant commitments to extra established managers transferring into the world of healthcare, like a dedication to Creation’s debut life sciences fund. It was a repeat investor in UK-based generalist funds with healthcare publicity equivalent to CBPE, NorthEdge, and Livingbridge.
The EIF’s assist had a multiplier impact on fundraising too, because the validation signaled by a dedication from the EIF typically inspired different restricted companions to decide to a fund. This was efficient at ‘crowding in’ capital from the personal sector domestically and from overseas. Abingworth Bioventures’ third fund, the final UK fund to obtain funding from the EIF with particulars obtainable on Preqin, noticed further funding from pension funds, foundations, and insurance coverage corporations based mostly within the US, Germany, Switzerland, and the UK.
General these funds have generated good returns and so the EIF programme has been a web contributor to EU coffers. Help by the EIF enabled a brand new supervisor to lift their first and second funds, following which they sometimes had sufficient observe report to proceed elevating institutional capital with out state sponsorship by the EIF.
Since Brexit the UK authorities has tried to fill the void left by the EIF – however has left a vital space unaddressed
The day Brexit took impact the UK now not fell throughout the EIF’s remit. In observe, commitments to new UK funds tapered off when it turned clear that Brexit would possibly turn out to be a actuality. The UK authorities’s answer has been to develop a substitute for the EIF within the type of the British Enterprise Financial institution (BBB), first launched in 2014. This has been a partial success, with the BBB proving very lively within the space of life sciences. The BBB has funded 3 early-stage funds with UK healthcare publicity – Zinc VC, Longwall Ventures, and Epidarex Capital.
However the change in funding from the EIF to the BBB got here with a change in technique, away from investing throughout the personal fairness spectrum and in the direction of solely early-stage enterprise capital (VC).
This will likely change because the BBB develops – it has solely been going for 11 years and continues to evolve its technique in partnership with UK plc. The EIF is 20 years older – established in 1994 and now 31 years previous. The EIF is bigger and better-financed than the BBB, in addition to being a part of the European Funding Financial institution (EIB). The EIB is sort of 70 years previous, has 4,273 staff and had a steadiness sheet of EUR 556bn in 2024.
However its smaller organizational scale and age, in recent times the BBB has put extra into personal fairness markets than its counterpart the EIF, adjusted for the dimensions of the related economies (UK vs EU). Nonetheless, the UK authorities’s resolution to prioritise VC to the exclusion of buyouts and progress has left a spot within the UK funding panorama for healthcare companies after the very early stage. Not solely have new healthcare buyout traders missed out on authorities backing to get a primary fund going, they’ve misplaced out on the worldwide capital which that backing typically attracted alongside.
This has left a funding hole – and a chance for personal sector traders to step in
The consequence has been the lack of a core state sponsor within the UK for brand spanking new personal fairness managers within the healthcare buyout and progress capital area, compounding an already tough fundraising atmosphere. This has added to the widely-acknowledged funding hole within the UK for companies in search of capital after early-stage enterprise rounds. It’s these small buyouts and progress stage investments which enhance the SMEs typically described as the expansion engine of western economies. It’s been well-publicized that managers get the most effective returns of their first one or two funds. May the door be open for adventurous healthcare traders within the personal sector to select up the chance missed by the UK’s authorities following Brexit, and safe good returns from new managers hungry to lift a primary healthcare buyout fund however struggling to search out an anchor?
Photograph: Wong Yu Liang, Getty Photos
David Jolly is Funding Director at Weight Companions Capital, an UK personal fairness agency investing in UK lower-mid market healthcare companies enterprise, the place he leads new transaction work and helps operational enhancements at portfolio corporations. David is a member of the Funding Committee and sits on the boards of a number of of WPC’s portfolio corporations. Earlier than becoming a member of the agency in 2011, David labored within the personal investments staff of the Canada Pension Plan Funding Board in Toronto, and on operational change initiatives at Credit score Suisse in London. David has a Bachelor of Commerce from Queen’s College in Canada, and an MSc in Finance and Non-public Fairness with distinction from the London College of Economics.
This submit seems by means of the MedCity Influencers program. Anybody can publish their perspective on enterprise and innovation in healthcare on MedCity Information by means of MedCity Influencers. Click on right here to learn the way.
